Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | baculoviral IAP repeat containing protein | 0.0062 | 0.1084 | 0.1084 |
Echinococcus granulosus | eukaryotic initiation factor 4A III | 0.0327 | 1 | 1 |
Schistosoma mansoni | inhibitor of apoptosis (iap) domain family member | 0.0062 | 0.1084 | 0.1084 |
Mycobacterium tuberculosis | Probable cold-shock DeaD-box protein A homolog DeaD (ATP-dependent RNA helicase dead homolog) | 0.0327 | 1 | 0.5 |
Trypanosoma brucei | Eukaryotic initiation factor 4A-1 | 0.0327 | 1 | 0.5 |
Plasmodium falciparum | eukaryotic initiation factor 4A | 0.0327 | 1 | 0.5 |
Echinococcus multilocularis | Glutamate receptor, ionotropic kainate 3 | 0.0033 | 0.0108 | 0.0108 |
Leishmania major | eukaryotic initiation factor 4a, putative | 0.0327 | 1 | 0.5 |
Echinococcus multilocularis | eukaryotic initiation factor 4A III | 0.0327 | 1 | 1 |
Plasmodium vivax | RNA helicase-1, putative | 0.0327 | 1 | 0.5 |
Entamoeba histolytica | DEAD/DEAH box helicase, putative | 0.0327 | 1 | 0.5 |
Leishmania major | eukaryotic initiation factor 4a, putative | 0.0327 | 1 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0062 | 0.1084 | 0.1084 |
Trypanosoma cruzi | Eukaryotic initiation factor 4A-1 | 0.0327 | 1 | 0.5 |
Trichomonas vaginalis | DEAD box ATP-dependent RNA helicase, putative | 0.0327 | 1 | 0.5 |
Echinococcus granulosus | eukaryotic initiation factor 4A | 0.0327 | 1 | 1 |
Onchocerca volvulus | Eukaryotic initiation factor 4A homolog | 0.0327 | 1 | 1 |
Trichomonas vaginalis | DEAD box ATP-dependent RNA helicase, putative | 0.0327 | 1 | 0.5 |
Treponema pallidum | ATP-dependent RNA helicase | 0.0327 | 1 | 0.5 |
Giardia lamblia | Translation initiation factor eIF-4A, putative | 0.0327 | 1 | 0.5 |
Echinococcus granulosus | nmda type glutamate receptor | 0.0033 | 0.0108 | 0.0108 |
Echinococcus multilocularis | eukaryotic initiation factor 4A | 0.0327 | 1 | 1 |
Echinococcus granulosus | baculoviral IAP repeat containing protein | 0.0062 | 0.1084 | 0.1084 |
Schistosoma mansoni | DEAD box ATP-dependent RNA helicase | 0.0327 | 1 | 1 |
Echinococcus multilocularis | nmda type glutamate receptor | 0.0033 | 0.0108 | 0.0108 |
Trypanosoma cruzi | Eukaryotic initiation factor 4A-1 | 0.0327 | 1 | 0.5 |
Trichomonas vaginalis | DEAD box ATP-dependent RNA helicase, putative | 0.0327 | 1 | 0.5 |
Echinococcus multilocularis | inhibitor of apoptosis protein | 0.0062 | 0.1084 | 0.1084 |
Toxoplasma gondii | eukaryotic initiation factor-4A, putative | 0.0327 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0327 | 1 | 1 |
Echinococcus granulosus | inhibitor of apoptosis protein | 0.0062 | 0.1084 | 0.1084 |
Schistosoma mansoni | inhibitor of apoptosis protein | 0.0062 | 0.1084 | 0.1084 |
Schistosoma mansoni | DEAD box ATP-dependent RNA helicase | 0.0327 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Diet (functional) | ND 0 % | In vivo Sterol lowering activity at dose as 0.10 % of the diet;ND means no data. | ChEMBL. | 6604816 |
Diet (functional) | ND 0 % | In vivo Triglyceride lowering activity at dose as 0.10 % of the diet;ND means no data. | ChEMBL. | 6604816 |
Diet (functional) | = 78 % | In vivo Triglyceride lowering activity at dose as 0.03 % of the diet. | ChEMBL. | 6604816 |
Diet (functional) | = 94 % | In vivo triglyceride lowering activity, dosed at 0.01 % of the diet. | ChEMBL. | 6604816 |
Diet (functional) | = 98 % | In vivo Sterol lowering activity at dose as 0.03 % of the diet. | ChEMBL. | 6604816 |
Diet (functional) | = 104 % | In vivo Sterol lowering activity at dose as 0.01 % of the diet. | ChEMBL. | 6604816 |
Inhibition (binding) | = 44 % | In vitro inhibitory activity against acyl coenzyme A:cholesterol acyltransferase (ACAT) | ChEMBL. | 6604816 |
Inhibition (binding) | = 44 % | In vitro inhibitory activity against acyl coenzyme A:cholesterol acyltransferase (ACAT) | ChEMBL. | 6604816 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.